<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015521</url>
  </required_header>
  <id_info>
    <org_study_id>TG-AFP-002</org_study_id>
    <nct_id>NCT01015521</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Aminoflavone Prodrug to Treat Breast Cancer</brief_title>
  <official_title>A Two-Arm Open Label Phase II Study of AFP464 (Aminoflavone Prodrug) in Previously-treated ER-positive or Triple-negative Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tigris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tigris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II study to assess the efficacy of Aminoflavone prodrug in triple negative
      and ER+ breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was not initiated as planned
  </why_stopped>
  <start_date>April 2010</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Benefit Response</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 monhts</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Breast Neoplasm</condition>
  <arm_group>
    <arm_group_label>Aminoflavone Prodrug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aminoflavone to treat ER positive breast cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aminoflavone Prodrug with pretreatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aminoflavone Prodrug to treat Triple Negative Breast Cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aminoflavone Prodrug</intervention_name>
    <description>Aminoflavone Prodrug administered D1, D8 of 21-day cycle</description>
    <arm_group_label>Aminoflavone Prodrug</arm_group_label>
    <arm_group_label>Aminoflavone Prodrug with pretreatment</arm_group_label>
    <other_name>AFP464</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ER+ or TN Breast Cancer

          -  Progression on an aromatase inhibitor if ER+

          -  Prior treatment with taxane if TN

          -  18 years or older

          -  Adequate organ function

          -  Measurable lesion

        Exclusion Criteria:

          -  symptomatic pulmonary disease

          -  brain metastases

          -  pregnant females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>November 1, 2010</last_update_submitted>
  <last_update_submitted_qc>November 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Binh Nguyen, MD PhD</name_title>
    <organization>Chief Medical Officer</organization>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

